LevophencynonateAlternative Names: (L)-phencynonate; (L)-phencynonate hydrochloride; L-hydrochloric acid phencynonate; L-LPC; L-phencynonate; L-phencynonate hydrochloride; Levo phencynonate hydrochloride; Levophencynonate hydrochloric; LH tablet
Latest Information Update: 26 Apr 2016
At a glance
- Originator Academy of Military Medical Sciences
- Developer Sihuan Pharmaceutical Holdings Group
- Class Antiemetics; Aza compounds; Glycolates
- Mechanism of Action Muscarinic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Vertigo